Insta
Cipla To Scale Up Remdesivir Production Two-Fold To Meet ‘Unprecedented Demand’ For The Drug
IANS
Apr 14, 2021, 10:49 AM | Updated 10:49 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Pharmaceutical company Cipla on Tuesday (13 April) said it has scaled up the production of remdesivir by two times from the last wave of the pandemic.
As the demand for the drug surges, the government has prohibited the exports of remdesivir injection and its active pharmaceutical ingredients (API).
"Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand," the company said in a statement.
"To ensure fair and equitable access, we are working with the regulatory authorities to restrict the supply of the drug only to hospital channels and especially those regions with a high burden of severe Covid-19," Cipla said.
On Tocilizumab, the company said that given the spike in cases and surge in demand, it is facing a shortage and working closely with its partner in taking necessary steps to ensure the availability of the drug.
"We expect intermittent supplies as the demand outstrips supply with some more receipts at the earliest," it added.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.